{
    "2018-09-06": [
        [
            {
                "time": "2018-09-05",
                "original_text": "New Class of Migraine Drug Creates Four-Way Pharma Development Race",
                "features": {
                    "keywords": [
                        "Migraine",
                        "Drug",
                        "Pharma",
                        "Development",
                        "Race"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-09-06",
                "original_text": "Pfizerâ€™s PF-06651600 Receives a Breakthrough Therapy Designation",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "PF-06651600",
                        "Breakthrough",
                        "Therapy",
                        "Designation"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-09-07",
                "original_text": "Lilly's Elanco unit expects IPO to raise up to $1.45 bln",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Elanco",
                        "IPO",
                        "Raise",
                        "$1.45 bln"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-08",
                "original_text": "Large Cap Pharma Stocks Staging a Comeback in Second Half",
                "features": {
                    "keywords": [
                        "Large Cap",
                        "Pharma",
                        "Stocks",
                        "Comeback",
                        "Second Half"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-09",
                "original_text": "Lilly Announces Webcast to Discuss EASD Presentations",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Webcast",
                        "EASD",
                        "Presentations"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-09-10",
                "original_text": "Eli Lilly's Elanco sets IPO terms to raise up to $1.45 billion before options",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Elanco",
                        "IPO",
                        "Raise",
                        "$1.45 billion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-11",
                "original_text": "Elanco Announces Launch of IPO Roadshow",
                "features": {
                    "keywords": [
                        "Elanco",
                        "IPO",
                        "Roadshow"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-12",
                "original_text": "J&J Submits NDA to the FDA for Depression Drug in Adults",
                "features": {
                    "keywords": [
                        "J&J",
                        "NDA",
                        "FDA",
                        "Depression",
                        "Drug"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}